Forvis Mazars advises on completed sale of leading medical device manufacturer Owen Mumford to US-listed Embecta

Forvis Mazars, a leading global professional services network, has advised Owen Mumford, a leading UK-based drug delivery and medical device manufacturer, and its shareholders on the completion of its sale to Embecta Corp., a US-listed global medical device company focused on improving the lives of people living with diabetes. 

The completed transaction reflects continued strong interest from overseas buyers in high-quality UK assets, particularly from the United States. This demand is underpinned by the heritage and global reputation of UK businesses, especially in sectors such as medical devices, where innovation, intellectual property and long-standing customer relationships are critical. 

The combination brings together two businesses with complementary capabilities and a shared commitment to innovation in drug delivery, strengthening Embecta’s legacy in insulin delivery and supporting its evolution into a broader medical supplies company. Together, Embecta and Owen Mumford combine more than 170 years of experience in developing high-quality, patient-focused solutions, underpinned by strong cultures and multi-generational employee relationships. 

The transaction attracted strong interest from international buyers, underlining the enduring appeal of UK-headquartered businesses with long-established expertise and specialist capabilities. It also demonstrates the continued view of UK assets as offering compelling value, access to innovation and established global customer bases.

Forvis Mazars acted as lead financial adviser to Owen Mumford, supporting the company and its shareholders throughout the transaction, including preparation for sale, marketing the business, soliciting offers from buyers, managing the due diligence process and supporting negotiations, working closely with the management team to deliver a successful outcome. 

Adam Mumford, a former shareholder of Owen Mumford, said, “As shareholders, selling our business was one of the most important and demanding decisions we have ever made, and Forvis Mazars proved to be exactly the professional advisors we needed. From the outset, they took the time to really understand our personal objectives and preferences and then executed the process in a disciplined and well-structured manner.”

The deal was led by Oliver Hoffman, supported Janice Clement-Smith, Arran Smedley and Tiffany Chan, drawing on our wider Deal Advisory expertise from across Forvis Mazars to support Owen Mumford, its management team and stakeholders through the transaction. 

Oliver Hoffman, Deal Advisory Partner, said: “The transaction marks a significant milestone for Owen Mumford, providing the scale and global reach to support its next phase of growth. It also underscores strong overseas appetite for high-quality UK businesses and the value of our integrated international model in delivering complex cross-border deals. Finding the right buyer was key, and Embecta represents an excellent fit - respecting the company’s values and legacy while enabling ambitious product development. I am delighted for all involved and proud to have supported this pioneering transaction in the medical devices space.” 

Nigel Layton, Global Head of Life Sciences & Pharma added: “This transaction underlines both the resilience of the pharmaceutical and medical device sector and the ongoing demand from international buyers for UK assets. Despite broader market uncertainty, businesses with strong intellectual property, long-standing customer relationships and a proven track record of innovation continue to attract significant interest - particularly from US investors seeking high-quality, established platforms.”

About the companies: 

Founded in 1952, Owen Mumford is a family‑owned designer and manufacturer of medical devices, specialising in drug delivery and blood sampling solutions. With more than 70 years of expertise, the business has built a strong reputation for innovative design, high‑quality products and long‑standing customer relationships. Operating across medical devices and pharmaceutical services, Owen Mumford supports global healthcare providers and pharmaceutical companies with mission‑critical solutions that improve patient outcomes. 

Embecta is a Nasdaq‑listed global medical device company with a 100‑year heritage in insulin delivery and a growing portfolio of medical supplies. Serving more than 30 million people in over 100 countries, Embecta is focused on advancing patient care through innovation, scale and deep partnerships across the healthcare ecosystem.